Venetoclax | ABT-199 | GDC-0199 | CAS#1257044-40-8 | BCL-2 Inhibitor | MedKoo
Model for ABT-199-resistance and PI3K-mTOR-mediated targeting of... | Download Scientific Diagram
![PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0ec51f354d5a228645aef51832a6d296b927bd6b/7-Figure4-1.png "PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar")
PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar
.gif "ABT-199 (Venetoclax) - Chemietek")
ABT-199 (Venetoclax) - Chemietek
Venetoclax (ABT-199) | ≥99%(HPLC) | Selleck | Bcl-2 inhibitor
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma | Leukemia
Venetoclax - Wikipedia
An Unexpected Halt in Multiple Myeloma for Venetoclax | Science | AAAS
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA | Cell Death & Disease
Functional evaluation of Bcl2 and BAX mutations. (A) ABT-199 was unable... | Download Scientific Diagram
Navitoclax - an overview | ScienceDirect Topics
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells - Jakubowska - 2019 - British Journal of Pharmacology - Wiley Online Library
ABT-199 activates the intrinsic mitochondrial apoptosis pathway in... | Download Scientific Diagram
Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines - ScienceDirect
Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2 | Personalized Medicine in Oncology
Venetoclax (ABT-199) | BCL-2 Inhibitor | MedChemExpress
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Signal Transduction and Targeted Therapy
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. - Abstract - Europe PMC
Practical Fragments: Second fragment-based drug approved
![PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fdf95a15ef1cbf1ab603cd15531b69fef7da162f/7-Figure5-1.png "PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar")
PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar
Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family members - Opferman - 2016 - The FEBS Journal - Wiley Online Library
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors | Haematologica
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
Identification of tivantinib and ABT-199 as a synergistic drug... | Download Scientific Diagram
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
